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ABSTRACT There has been a resurgence of interest in aerosolization of antibiotics
for treatment of patients with severe pneumonia caused by multidrug-resistant
pathogens. A combination formulation of amikacin-fosfomycin is currently undergo-
ing clinical testing although the exposure-response relationships of these drugs have
not been fully characterized. The aim of this study was to describe the individual
and combined antibacterial effects of simulated epithelial lining ﬂuid exposures of
aerosolized amikacin and fosfomycin against resistant clinical isolates of Pseudomo-
nas aeruginosa (MICs of 16 mg/liter and 64 mg/liter) and Klebsiella pneumoniae (MICs
of 2 mg/liter and 64 mg/liter) using a dynamic hollow-ﬁber infection model over 7
days. Targeted peak concentrations of 300 mg/liter amikacin and/or 1,200 mg/liter
fosfomycin as a 12-hourly dosing regimens were used. Quantitative cultures were
performed to describe changes in concentrations of the total and resistant bacterial
populations. The targeted starting inoculum was 108 CFU/ml for both strains. We
observed that neither amikacin nor fosfomycin monotherapy was bactericidal
against P. aeruginosa while both were associated with rapid ampliﬁcation of re-
sistant P. aeruginosa strains (about 108 to 109 CFU/ml within 24 to 48 h). For K.
pneumoniae, amikacin but not fosfomycin was bactericidal. When both drugs
were combined, a rapid killing was observed for P. aeruginosa and K. pneu-
moniae (6-log kill within 24 h). Furthermore, the combination of amikacin and
fosfomycin effectively suppressed growth of resistant strains of P. aeruginosa and
K. pneumoniae. In conclusion, the combination of amikacin and fosfomycin was
effective at maximizing bacterial killing and suppressing emergence of resistance
against these clinical isolates.
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For patients with pneumonia, the epithelial lining ﬂuid (ELF) is an important sub-compartment for a complete understanding of drug exposure-response relation-
ships. Several factors can affect penetration of a systemically administered antibiotic
into the ELF, including the blood-bronchus barrier, drug protein binding, physicochem-
ical properties of the drug (hydrophilic-lipophilic balance and molecular size), pH at site
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of infection, and the degree of ionization of drug molecules (1, 2). While substantial
penetration into the ELF has been observed for some antibiotics, for many others the
concentrations achieved in the ELF may be subtherapeutic, particularly when the MIC
for the etiologic organism is high, as commonly observed with pathogens like Pseu-
domonas aeruginosa (2) which commonly cause severe pneumonia. Hydrophilic anti-
biotics such as aminoglycosides are considered to poorly penetrate into the ELF and
have a low probability of achieving therapeutic concentrations with systemic admin-
istration (2). Consequently, there is a high risk of clinical failure as well as of the
emergence of resistant bacteria when pathogenic bacteria are exposed to suboptimal
concentrations of antibiotic.
The inhalation route of administration may enable the delivery of effective antibiotic
concentrations into the lungs (3). Given the strong relationship between antibiotic
exposure and bacterial killing as described in in vitromodels, optimizing concentrations
at the site of infection may lead to improved clinical effects. A number of antibiotics
have now been speciﬁcally formulated into aerosolized dosage forms although phar-
macokinetic/pharmacodynamic (PK/PD) studies to conﬁrm the microbiological effects
of the high concentrations of antibiotics associated with this mode of administration
remain sparse (4). One promising therapeutic option is a combination amikacin-
fosfomycin product, which is currently being tested for clinical effectiveness (Clinical-
Trials.gov identiﬁer NCT02218359 [https://clinicaltrials.gov/ct2/show/NCT02218359]). It
is administered via an investigational eFlow inline nebulizer system in mechanically
ventilated patients. While promising results have been reported in early-phase clinical
studies (5), the pharmacodynamic interaction of the combination regimen with the
inhalational dose for clinical use is yet to be fully elucidated.
The aim of this study was to describe the individual and combined antibacterial
effects (bacterial killing and suppression of emergence of resistance) of simulated
epithelial lining ﬂuid exposures of amikacin and fosfomycin when they are adminis-
tered by the inhalational route against clinical isolates of P. aeruginosa and Klebsiella
pneumoniae.
RESULTS
In vitro susceptibility. Results of the susceptibility testing by the EUCAST and CLSI
methods were similar. The MICs of amikacin for the P. aeruginosa clinical isolate (PA SAT
290) and the K. pneumoniae clinical isolate (K.p. 301) were 16 and 2 mg/liter, respec-
tively, whereas the MIC of fosfomycin for both clinical isolates was 64 mg/liter.
Mutation frequency. The mutational frequencies of P. aeruginosa clinical isolate PA
SAT 290 at a concentration of four times the MIC were 2.37  106 against fosfomycin
and 1.32  108 for amikacin alone or for amikacin in combination with fosfomycin.
The mutational frequencies of K. pneumoniae clinical isolate K.p. 301 at four times the
MIC were 6.96  106, 2.00  105, and 8.7  1010 against fosfomycin, amikacin,
and the combination of amikacin and fosfomycin, respectively.
HFIM. The measured concentrations of amikacin and fosfomycin were close to
expected concentrations considering linear pharmacokinetic decay, with half-lives of 3
h and 6 h, respectively (Fig. 1). Figure 2 summarizes the results of a hollow-ﬁber
infection model (HFIM) investigation of the effect of amikacin-fosfomycin combination
therapy on the total bacterial population of PA SAT 290 (P. aeruginosa) in comparison
with monotherapy with each drug. Amikacin monotherapy showed only transient initial
bacterial killing (about 2 logs) with rapid regrowth within 72 h such that the total
bacterial concentration was comparable to that of the control arm with no drug
treatment. Fosfomycin monotherapy, on the other hand, did not show any bacterial
killing during the entire course of treatment. In contrast, treatment with the combina-
tion of amikacin and fosfomycin resulted in rapid bacterial killing with complete
eradication of the bacterial population within 72 h. The bactericidal activity of the
combination was sustained throughout the 7-day experiment with no regrowth.
The effect of the amikacin-fosfomycin combination on the resistant bacterial pop-
ulation of PA SAT 290 (P. aeruginosa) is illustrated in Fig. 3. Monotherapy with each drug
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resulted in rapid growth of resistant strains, which increased to a density of approxi-
mately 108 to 109 CFU/ml within 24 to 48 h. No growth of amikacin-resistant strains was
observed after the combination therapy, whereas in the control arm growth of
amikacin-resistant strains was observed throughout the 7 days of treatment. Similarly,
there was a steady population of fosfomycin-resistant strains in the control arm
(approximately 104 CFU/ml) over the 7-day experiment. However, the combination
therapy was effective in suppressing the growth of fosfomycin-resistant strains, result-
ing in complete eradication after 72 h.
Figure 4 shows the effect of amikacin and/or fosfomycin therapy on total bacterial
density of the K. pneumoniae clinical isolate (K.p. 301). Monotherapy with amikacin was
effective in achieving maximal bacterial killing, unlike monotherapy with fosfomycin,
which showed only transient initial killing followed by rapid regrowth that plateaued at
a bacterial density comparable to that of the untreated control (Fig. 4). The combina-
tion therapy with similar target amikacin-fosfomycin peak concentrations resulted in
faster bacterial killing. Further examination of the effect of the combination therapy on
the resistant population (Fig. 5) shows no growth of resistant subpopulations that
existed at baseline. However, fosfomycin monotherapy was associated with a rapid
increase in the density of a fosfomycin-resistant population, peaking within 12 h, while
in the untreated control there was no increase in the fosfomycin-resistant population
from the baseline level.
FIG 1 Observed concentration-time proﬁles of amikacin and fosfomycin during the ﬁrst dosing interval.
FIG 2 The effect of amikacin-fosfomycin combination therapy on the density of the total bacterial
population of a P. aeruginosa clinical isolate (PA SAT 290) in an HFIM simulating pharmacokinetic decay
of peak concentrations of 300 mg/liter amikacin–1,200 mg/liter fosfomycin in comparison with growth
with monotherapy with each antibiotic.
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DISCUSSION
Considering the EUCAST clinical susceptibility breakpoints of conventional systemic
(intravenous) dosing regimens of amikacin and fosfomycin, neither of the clinical
isolates investigated in this study was susceptible to either antibiotic with the excep-
tion of the K. pneumoniae isolate, which was susceptible to amikacin. Thus, the
infections caused by these nonsusceptible pathogens would not be considered treat-
able by conventional systemic therapy with either amikacin or fosfomycin. An inhala-
tional mode of administration may enable the achievement of bactericidal concentra-
tions at the site of infection and act as an adjunct to coadministered systematic
antibiotic therapy (4, 6). High concentrations of amikacin and fosfomycin can be
achieved in the epithelial lining ﬂuid by this mode of drug administration while
systemic exposure remains minimal, thereby potentially avoiding well-described tox-
icities (5, 7). In the current study, we assessed the pharmacodynamics of simulated
epithelial lining ﬂuid concentrations of amikacin and fosfomycin, alone and in combi-
nation, to describe effect on bacterial killing and suppression of resistance.
Our results suggest that the amikacin-fosfomycin combination achieves improved
bacterial killing against P. aeruginosa compared to that with monotherapy (Fig. 2). In
comparison, fosfomycin monotherapy had little discernible effect. For amikacin mono-
therapy, although initial bacterial killing at 12 h was similar to that of the combination,
later bacterial killing was signiﬁcantly lower than that observed with the combination.
FIG 3 The effect of amikacin-fosfomycin combination therapy on the density of resistant bacterial popu-
lations of a P. aeruginosa clinical isolate (PA SAT 290) in an HFIM simulating pharmacokinetic decay of peak
concentrations of 300 mg/liter amikacin–1,200 mg/liter fosfomycin in comparison with growth with
monotherapy with each antibiotic.
FIG 4 The effect of amikacin-fosfomycin combination therapy on the density of the total bacterial
population of a K. pneumoniae clinical isolate (K.p. 301) in an HFIM simulating pharmacokinetic decay of
peak concentrations of 300 mg/liter amikacin–1,200 mg/liter fosfomycin in comparison with growth with
monotherapy with each antibiotic.
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Similarly, more rapid bacterial killing was observed with the combination than with the
monotherapies against the K. pneumoniae isolate (Fig. 4). Indeed, both monotherapies
showed greater effects than those against the P. aeruginosa isolate, with fosfomycin
showing modest bacterial killing in the ﬁrst 8 h, after which there were no obvious
effects. Amikacin alone was more signiﬁcantly bactericidal than fosfomycin and then
suppressed growth of the K. pneumoniae for the duration of the experiment.
Although the exact molecular mechanisms are unknown, the pharmacodynamic
interaction between fosfomycin and an aminoglycoside antibiotic may occur due to
enhanced access for the aminoglycoside to the target site within the bacterial ribo-
some. Aminoglycosides, which are hydrophilic molecules, may have a submaximal
distribution across the cell wall into their binding sites in the cytosol (ribosomes) that
could be a limiting factor for their antibacterial action and an important mechanism of
resistance (8). Fosfomycin works by interfering with an initial step in the synthesis of
building blocks of the bacterial cell wall, thereby disrupting the integrity of this
important barrier (9). Consequently, it may enhance penetration of aminoglycoside
drug molecules into the bacterial cells. For example, MacLeod et al. (10) demonstrated
that fosfomycin enhances uptake of a radiolabeled [3H]tobramycin in a dose-
dependent manner by interfering with either active or passive uptake processes in P.
aeruginosa. Consistent with our ﬁndings for amikacin against P. aeruginosa (Fig. 2), the
authors also demonstrated that enhanced bacterial killing by tobramycin was observed
when it was combined with fosfomycin.
In addition to improved bacterial killing, the current study showed that the com-
bination effectively prevented emergence of the resistant subpopulations observed
with either amikacin or fosfomycin alone against the P. aeruginosa isolate (Fig. 3). For
the K. pneumoniae isolate, no growth of an amikacin-resistant subpopulation was
observed after monotherapy (Fig. 5), while there was a steady subpopulation of
resistant strains in the control treatment arm. Given that the K. pneumoniae isolate was
generally susceptible to amikacin and that amikacin exhibits concentration-dependent
killing, it is likely that the relatively high concentration (300 mg/liter) resulted in a
bactericidal effect against these less susceptible subpopulations. For fosfomycin on the
other hand, monotherapy resulted in rapid growth of resistant populations, consistent
with previous reports of its use against Gram-negative bacteria (11–13). However, when
fosfomycin was combined with amikacin, the fosfomycin-resistant subpopulations were
completely eradicated.
This study has several limitations. First, it fails to account for the host immune
response, in the presence of which the exposure-response relationship may be differ-
ent. Nonetheless, HFIM is considered highly predictive of clinical microbiological out-
comes. Another important limitation is that only two clinical isolates were investigated,
and the number of observations per treatment arm was limited due to the high cost of
running the HFIM. Further, given the lack of data on the airway pharmacokinetics of the
FIG 5 The effect of amikacin-fosfomycin combination therapy on the density of resistant bacterial popu-
lations of a K. pneumoniae clinical isolate (K.p. 301) in an HFIM simulating pharmacokinetic decay of peak
concentrations of 300 mg/liter amikacin–1,200 mg/liter fosfomycin in comparison with growth with
monotherapy with each antibiotic.
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study antibiotics, the simulated concentrations were based on the assumption of
similar pharmacokinetic decay patterns observed with systemic therapy. Thus, the
simulated concentrations provide only a gross approximation of airway exposure given
the current understanding of the study drugs’ pharmacokinetics.
In conclusion, the ﬁndings of this study support the aerosolization of the amikacin-
fosfomycin combination to enable high drug concentrations in the airway so as to
rapidly decrease bacterial burden and prevent the emergence of resistant subpopula-
tions, particularly against highly resistant infections. Further, the results demonstrate
that monotherapy with either amikacin or fosfomycin can risk emergence of resistant
subpopulations, which can be effectively suppressed by the combination of these
antibiotics. It therefore appears advantageous to use the amikacin-fosfomycin combi-
nation to maximize bacterial killing and suppress the emergence of resistance.
MATERIALS AND METHODS
Antimicrobial agents. For in vitro susceptibility testing, analytical reference standards of amikacin
and fosfomycin were used. For hollow-ﬁber infection model (HFIM) studies, amikacin solution (pH 7.0;
100 mg/ml amikacin base, 3-ml ampoules) and fosfomycin solution (pH 8.0; 40 mg/ml fosfomycin base,
3-ml ampoules) were supplied by Cardeas Pharma and used undiluted by taking an appropriate volume
corresponding to the required dose of simulated peak concentrations. Fosfomycin ampoules were stored
in a refrigerator until just before dosing when the required volume for injection was transferred into a
sterile delivery syringe in a biosafety cabinet. Similarly, amikacin ampoules were stored in the original
package at room temperature, and just before dosing, the required volume was aspirated into the
delivery sterile syringe in a biosafety cabinet.
Bacterial isolates. A clinical isolate of P. aeruginosa (PA SAT 290) sourced from patients with
ventilator-associated pneumonia as part of an ongoing therapeutic trial was supplied by Cardeas
Pharma. A clinical isolate of K. pneumoniae (K.p. 301) was obtained from the Antimicrobial Pharmaco-
dynamics and Therapeutics Group, Department of Molecular and Clinical Pharmacology, the University
of Liverpool. All bacteria were stored in cation-adjusted Mueller-Hinton II broth (CA-MH) containing 10%
glycerol in a freezer at 80°C. Prior to each experiment, fresh isolates were grown on Mueller-Hinton
agar plates incubated at 37°C for 24 h and used for the preparation of all inocula. For the hollow-ﬁber
studies, the bacterial suspension for inoculation was prepared by taking ﬁve colonies of bacteria from the
freshly grown agar plates and incubating them in 40 ml of CA-MH broth at 37°C for 24 h with constant
agitation. Based on prior growth curve analysis, these amounts would give an inoculum concentration
of about 1  108 CFU/ml. The concentrations of the bacterial suspension in the ﬁnal inoculum were
conﬁrmed by quantitative cultures.
In vitro susceptibility testing. The broth microdilution method was used for determination of the
MIC for the organisms in accordance with the recommendations of the Clinical and Laboratory Standards
Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing EUCAST (14, 15). In brief,
serial 2-fold dilutions of each antibiotic were prepared in CA-MH broth and aliquoted into round-bottom
microtiter plates (CLSI tests) and ﬂat-bottom microtiter plates (EUCAST test). A standardized inoculum
suspension prepared in CA-MH broth was then added to yield approximately 5  105 CFU/ml. For
fosfomycin susceptibility tests, all of the CA-MH broth used was supplemented with 25 mg/liter
glucose-6-phosphate. The inoculated plates were then incubated at 37°C for 16 to 20 h. The optical
density of each well in the ﬂat-bottom microtiter plates was read using EUCAST MIC read software
coupled to a Multiskan FC Microplate Photometer (Thermo Scientiﬁc). The lowest concentration of
the antibiotic that resulted in a blank-subtracted optical density value of less than 0.1 times that of
the positive growth control was identiﬁed as the MIC90. For the round-bottom microtiter plates, the
lowest concentration of the antibiotic that completely inhibited growth was visually identiﬁed as the
MIC in accordance with the CLSI recommendations. MIC tests were run in 10 replicates (ﬁve
replicates for each method) on two different occasions; the mode of the determined values was
reported as the MIC.
Mutation frequency (MF). To assess the frequency of mutation that leads to emergence of
resistance, ﬁrst an initial inoculum of 102 CFU/ml was incubated in CA-MH broth for 24 h at 37°C. Next,
the total bacterial concentration was estimated by plating on drug-free CA-MH agar plates and
drug-containing CA-MH agar plates (at 4 MIC). The bacterial concentration was determined by
quantitative culture, and the drug resistance frequency was estimated from the ratio of growth found on
the drug-containing plates after 48 h of incubation to that of the starting inoculum.
HFIM. The circuit system for the hollow-ﬁber infection (HFIM) model was set up as previously
described (16). FiberCell Systems cartridge C2011 was used for all experiments. In the experiments
investigating the amikacin-fosfomycin combination, a supplementing compartment was introduced to
simulate the differential clearance of the two antibiotics in accordance with the method described by
Blaser (17). The CA-MH broth used in all experiments was supplemented with 25 mg/liter glucose-6-
phosphate.
Given the lack of data on the airway pharmacokinetics of the study drugs, simulated concentration-
time proﬁles were based on assumed half-lives inferred from systemic therapy (3 h and 6 h for amikacin
and fosfomycin, respectively) (18, 19). Since very high concentrations of amikacin and fosfomycin can be
achieved with aerosolized administration (5, 7), with potential mucin antagonism (95%) and a low to
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moderate exposure from this mode of delivery, the effects of monotherapy with amikacin or fosfomycin
against the P. aeruginosa and K. pneumoniae clinical isolates were investigated at the target peak
concentrations of 300 mg/liter amikacin and 1,200 mg/liter fosfomycin. The antibacterial effect of the
combination was also studied using initial concentrations of 300 mg/liter amikacin plus 1,200 mg/liter of
fosfomycin. In all of the HFIM studies, the antibiotics were dosed every 12 h as a bolus infusion for a 7-day
duration. Control experiments with no drug treatment were run simultaneously under the same
conditions as used for the treatment arms. Quantitative cultures were performed on bacterial samples
taken from the extracapillary space of the hollow-ﬁber cartridge to determine the concentrations of the
total bacteria and of the resistant population. For these analyses, serial samples were taken on day 1
before administration of the ﬁrst drug(s) dose at 4 h, 8 h, and 12 h and subsequently before adminis-
tration of each dose for the rest of the 7-day experiment. Samples were washed with sterile phosphate-
buffered saline, and the concentrations of the total bacterial population and of the drug-resistant
subpopulation were determined by plating on drug-free and drug-containing CA-MH agar plates (at four
times the MIC of the bacteria).
Drug assay. Fosfomycin concentrations were measured using a validated ultrahigh-performance
liquid chromatography tandem mass spectrometry method. Brieﬂy, fosfomycin was extracted by protein
precipitation. Three hundred microliters of acetonitrile containing the internal standard (IS) ethylphos-
phonic acid at 10 g/ml was added to 100 l of broth. The samples were then mixed for 2 min and
passed through a protein precipitation plate (Sirocco, Waters) using positive pressure. One volume of the
supernatant was then mixed with one volume of 5 mM ammonium acetate, pH 4.8, and 5 l was injected
on an Agilent Zorbax Rapid Resolution High Deﬁnition (RRHD) HILIC Plus column (hydrophilic interaction
chromatography column; 2.1 by 50 mm, 1.8-m particle size). Chromatographic separation was achieved
using 90:10 acetonitrile–50 mM ammonium acetate (pH 4.8) as mobile phase A and 50:40:10 acetoni-
trile–water–50 mM ammonium acetate (pH 4.8) as mobile phase B. Mobile phase A at 100% was kept
for a minute, followed by an isocratic step at 100% mobile phase B for 2 min and 3 min of
equilibration. A G6420A Agilent triple quadrupole mass spectrometer was employed for detection.
The mass spectrometer was operated in multiple reaction monitoring (MRM) scan mode in negative
polarity. The precursor ion for fosfomycin was m/z 137, and it was m/z 109 for the IS. The product
ion for both was m/z 79. The source parameters were set as 3,500 V for capillary voltage, 350°C for
gas temperature, and 40 lb/in2 for the nebulizer gas. All validation data were within the require-
ments of guidelines (20).
Amikacin concentrations were determined using an immunoassay technique according to the
manufacturer’s guidelines (Cobas Kit AMIK2; Roche Diagnostics) at the clinical laboratory of the Royal
Liverpool Hospital, United Kingdom.
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